Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
published in: The American Journal of Gastroenterology
date of publication: 2005-11-01
language: English
main subject: colitis
Cites articles 8
- 2002-08-08
Date
Title
Article - wd:Q46798247